Briacell Therapeutics Corp. Common Shares - BCTX STOCK NEWS

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has developed Bria-OTS™, a novel off-the-shelf personalized immunotherapy for advanced breast cancer, discussed during the AACR Annual Meeting 2022. This innovative treatment aims to match patients' HLA types using a simple saliva test, enhancing the likelihood of clinical benefits. The Bria-OTS™ therapy utilizes genetically modified cell lines to cater to over 99% of the population, accelerating treatment without complex manufacturing processes. An open-label Phase I/IIa clinical trial is anticipated to evaluate its safety and efficacy.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has developed Bria-OTS™, an off-the-shelf personalized immunotherapy for advanced breast cancer. Currently in production at a cGMP facility, Bria-OTS™ is undergoing quality control testing in preparation for an upcoming Phase I/IIa clinical trial. Collaborating with the National Cancer Institute, BriaCell aims to optimize treatment based on patients' HLA types. The company will present details about Bria-OTS™ at the American Association for Cancer Research Annual Meeting on April 12, 2022.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces the recruitment of two new clinical sites for a Phase I/IIa study of its lead candidate, Bria-IMT™, combined with Incyte’s retifanlimab and epacadostat for advanced breast cancer. New sites include Atlantic Health System in New Jersey and Tranquil Clinical Research in Texas, enhancing patient access across the U.S. BriaCell emphasizes the urgent need for effective treatments in advanced breast cancer, collaborating with notable oncologists in these locations for patient care.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has appointed immunologist Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board. Kharazi, co-inventor of Bria-IMT™, brings over 30 years of expertise in immunotherapy, having held prominent roles in various institutions and holds multiple patents. This strategic addition is expected to enhance BriaCell’s efforts in developing targeted immunotherapies for advanced breast cancer, as noted by President & CEO Bill Williams, highlighting Kharazi’s knowledge as a significant asset.

BriaCell Therapeutics Corp. (BCTX, BCTXW) announces the appointment of Dr. Giuseppe Del Priore as Chief Medical Officer, effective immediately. He will manage clinical and regulatory aspects of ongoing and future trials, including a Phase I/IIa study of Bria-IMT™ combined with checkpoint inhibitors in advanced breast cancer patients. Dr. Del Priore brings over 25 years of oncology experience and has held leadership roles in clinical trials management. His appointment is expected to advance BriaCell's mission to provide innovative therapies for cancer patients with limited options.

BriaCell Therapeutics (BCTX, BCTXW) has been selected to present at the AACR Annual Meeting 2022, showcasing its innovative cancer immunotherapy. The company also continues its corporate buyback program, having repurchased over 1 million shares and warrants since its inception. Additionally, insiders plan to individually acquire approximately 1.59 million shares, representing 10% of the company's common shares. With approximately $52 million in cash and no debt, BriaCell aims to enhance shareholder value through these strategic initiatives.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that all resolutions at the Annual and Special Meeting of Shareholders held on January 18, 2022, were approved. This includes the election of directors, setting the number of directors at seven, re-appointment of auditors MNP LLP, approval of the stock option plan, and an amendment to create a new class of subordinate voting shares. The voting results showed strong support, with director nominees receiving over 97% approval. Detailed voting results are filed on SEDAR.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that its common shares will start trading on the Toronto Stock Exchange (TSX) on December 31, 2021. Concurrently, the shares will be de-listed from the TSX Venture Exchange. The normal-course issuer bid (NCIB) will continue under the new trading venue. The average daily trading volume prior to the NCIB was 15,073 shares, with a daily purchase limit of 3,768 shares on the TSX. BriaCell focuses on targeted immunotherapies for advanced breast cancer and other malignancies.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces insider intentions to acquire approximately 1.59 million common shares, representing 10% of the company's outstanding shares, starting January 31, 2022. Concurrently, the corporate buyback program continues, with 501,703 shares and 143,236 warrants repurchased to date. The company has raised $5.1 million from warrant exercises since November 1, 2021. With a cash balance of $55.5 million and no debt, BriaCell is well-positioned to pursue its cancer immunotherapy growth plans while enhancing shareholder value through these strategies.